Skip to main content

Advertisement

SpringerLink
Log in

The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The present review aims to systematically assess published data to elucidate benralizumab efficacy on nasal outcomes in comorbid patients.

Recent Findings

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease of the nasal cavity often associated with severe asthma (SA), contributing to a global disease burden in asthmatics. The two pathologies share common underlying mechanisms (e.g., type-2 inflammation), which sustain symptoms and poor comorbid patient quality of life. Therefore, it is of primary importance to identify the correct therapeutic option in order to achieve the optimal management of patients affected by both pathologies. Benralizumab is a humanized monoclonal antibody directed at the α subunit of the interleukin-5 receptor (IL-5Rα) approved for the treatment of severe eosinophilic asthma. Increasing body of literature provides data on its efficacy also on CRSwNP in the comorbid SA patient.

Summary

Based on the data described in this review, when benralizumab is administered to comorbid patients, it does not only control severe asthma but also improves CRSwNP clinical outcomes, although we need further studies to add stronger evidence and to improve the correct pheno-endotyping of the comorbid patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.

    Article  CAS  PubMed  Google Scholar 

  2. Hekking P-PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896–902.

  3. Massoth L, Anderson C, McKinney KA. Asthma and chronic rhinosinusitis: diagnosis and medical management. Med Sci (Basel). 2019;7:53.

    CAS  PubMed  Google Scholar 

  4. Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9:1133–41.

    Article  CAS  PubMed  Google Scholar 

  5. Heffler E, Blasi F, Latorre M, Menzella F, Paggiaro P, Pelaia G, et al. The severe asthma network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2019;7:1462–8.

    Article  PubMed  Google Scholar 

  6. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45–53.

    PubMed  PubMed Central  Google Scholar 

  7. Canonica GW, Malvezzi L, Blasi F, Paggiaro P, Mantero M, Senna G, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166: 105947.

    Article  PubMed  Google Scholar 

  8. Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5:1061-1070.e3.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists Rhinology. 2012;50:1–12.

    PubMed  Google Scholar 

  10. Alobid I, Benítez P, Bernal-Sprekelsen M, Roca J, Alonso J, Picado C, et al. Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy. 2005;60:452–8.

    Article  CAS  PubMed  Google Scholar 

  11. Mullol J, Azar A, Buchheit KM, Hopkins C, Bernstein JA. Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era. J Allergy Clin Immunol Pract. 2022;10:1434-1453.e9.

    Article  CAS  PubMed  Google Scholar 

  12. Mullol J, Maldonado M, Castillo JA, Miguel-Blanco C, Dávila I, Domínguez-Ortega J, et al. Management of united airway disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review. J Allergy Clin Immunol Pract. 2022;10:2438-2447.e9.

    Article  PubMed  Google Scholar 

  13. Mullol J, Maldonado M, Castillo JA, Miguel-Blanco C, Dávila I, Domínguez-Ortega J, Blanco-Aparicio M. Management of united airway disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review. J Allergy Clin Immunol Pract. 2022;10(9):2438-2447.e9.

    Article  PubMed  Google Scholar 

  14. Hulse KE, Stevens WW, Tan BK, Schleimer RP. Pathogenesis of nasal polyposis. Clin Exp Allergy. 2015;45:328–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Håkansson K, Bachert C, Konge L, Thomsen SF, Pedersen AE, Poulsen SS, et al. Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the united airways concept further supported. PLoS ONE. 2015;10: e0127228.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8:00576–2021.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Mullur J, Steger CM, Gakpo D, Bensko JC, Maurer R, Laidlaw TM, et al. Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience. Ann Allergy Asthma Immunol. 2022;128:575–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. De Corso E, Montuori C, Settimi S, Mele DA, Cantiani A, Corbò M, et al. Efficacy of biologics on refractory eosinophilic otitis media associated with bronchial asthma or severe uncontrolled CRSwNP. J Clin Med. 2022;11:926.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Iino Y. Eosinophilic otitis media; state-of-the-art diagnosis and treatment. Auris Nasus Larynx. 2022;S0385–8146(22):00225–35.

    Google Scholar 

  20. de Groot JC, Ten Brinke A, Bel EHD. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1:00024–2015.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160:814–30.

  22. Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J. Clin Med. 2019;8:1375.

    CAS  Google Scholar 

  23. Maio S, Baldacci S, Bresciani M, Simoni M, Latorre M, Murgia N, et al. RItA: the Italian severe/uncontrolled asthma registry. Allergy. 2018;73:683–95.

    Article  CAS  PubMed  Google Scholar 

  24. Menzella F, Bargagli E, Aliani M, Bracciale P, Brussino L, Caiaffa MF, et al. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. Respir Res. 2022;23:36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, et al. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Biomed Res Int. 2018;2018:4839230.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Dagher R, Kumar V, Copenhaver AM, Gallagher S, Ghaedi M, Boyd J, et al. Novel mechanisms of action contributing to benralizumab’s potent anti-eosinophilic activity. Eur Respir J. 2022;59:2004306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Matucci A, Vivarelli E, Nencini F, Maggi E, Vultaggio A. Strategies targeting type 2 inflammation: from monoclonal antibodies to JAK-inhibitors. Biomedicines. 2021;9:1497.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Mümmler C, Dünzelmann K, Kneidinger N, Barnikel M, Munker D, Gröger M, Canis M, Behr J, Koch A, Haubner F, Milger K. Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. Clin Transl Allergy. 2021;11(5): e12049.

    Article  PubMed  PubMed Central  Google Scholar 

  29. FitzGerald JM, Bleecker ER, Bourdin A, Busse WW, Ferguson GT, Brooks L, et al. Two-year integrated efficacy and safety analysis of benralizumab in severe asthma. J Asthma Allergy. 2019;12:401–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kavanagh JE, Hearn AP, Dhariwal J, d’Ancona G, Douiri A, Roxas C, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159:496–506.

    Article  CAS  PubMed  Google Scholar 

  31. Chung Y, Katial R, Mu F, Cook EE, Young J, Yang D, et al. Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study. Ann Allergy Asthma Immunol. 2022;128:669-676.e6.

    Article  CAS  PubMed  Google Scholar 

  32. Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52:1800936.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Nolasco S, Crimi C, Pelaia C, Benfante A, Caiaffa MF, Calabrese C, et al. Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study. J Allergy Clin Immunol Pract. 2021;9:4371-4380.e4.

    Article  CAS  PubMed  Google Scholar 

  34. Mauer Y, Taliercio RM. Managing adult asthma: the 2019 GINA guidelines. Cleve Clin J Med. 2020;87:569–75.

    Article  PubMed  Google Scholar 

  35. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

  36. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. •• Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021;9:260–74. First randomized clinical trial assessing the efficacy and safety of benralizumab in SEA patients with a subpopulation diagnosed with CRSwNP.

    Article  CAS  PubMed  Google Scholar 

  38. Canonica GW, Harrison TW, Chanez P, Menzella F, Louis R, Cosio BG, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. 2022;77:150–61.

    Article  CAS  PubMed  Google Scholar 

  39. Chitguppi C, Patel P, Gandler A, Murphy K, Khoury MdT, Monostra P, et al. Effect of benralizumab in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a case series. Am J Rhinol Allergy. 2021;35:559–67.

    Article  PubMed  Google Scholar 

  40. Barroso B, Valverde-Monge M, Alobid I, Olaguibel JM, Rial MJ, Quirce S, et al. Smell improvement by anti-IgE and anti-IL 5 biologics in patients with CRSwNP and severe asthma. A real life study. J Investig Allergol Clin Immunol. 2022;0.

  41. Santomasi C, Buonamico E, Dragonieri S, Lulaj E, Maselli L, Iorillo I, et al. Effects of benralizumab in patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. Eur Respir J. 2022;60:575.

    Google Scholar 

  42. •• Bagnasco D, Brussino L, Bonavia M, Calzolari E, Caminati M, Caruso C, et al. Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med. 2020;171: 106080. Benralizumab confirmed its efficacy in severe asthma and nasal polyposis. The efficacy of benralizumab in reducing steroid dependence was even higher in patients with polyposis.

    Article  PubMed  Google Scholar 

  43. • Cavaliere C, Segatto M, Ciofalo A, Colizza A, Minni A, Messineo D, et al. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a pilot real-life study. Immunol Lett. 2022;248:70–7. Pilot real-life study conducted with an anti-IL5R monoclonal antibody in severe eosinophilic asthma and severe CRSwNP patients showing that this treatment can induce benefit in both diseases.

    Article  CAS  PubMed  Google Scholar 

  44. • Lombardo N, Pelaia C, Ciriolo M, Della Corte M, Piazzetta G, Lobello N, et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol. 2020;34:2058738420950851. Real-life study evaluating effectiveness of the IL-5R blocker benralizumab on chronic rhinosinusitis with nasal polyposis (CRSwNP), associated with severe eosinophilic allergic asthma.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Tiotiu A, Mendez-Brea P, Ioan I, Romero-Fernandez R, Oster JP, Hoang T-C-T, et al. Real-life effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps. Clin Rev Allergy Immunol. 2022.

  46. Buonamico E, Dragonieri S, Sciancalepore PI, Carratù P, Carpagnano GE, Resta O, et al. Assessment of eosinophilic nasal inflammation in patients with severe asthma and nasal polyposis before and after six months of therapy with benralizumab. J Biol Regul Homeost Agents. 2020;34:2353–7.

    CAS  PubMed  Google Scholar 

  47. •• Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149:1309-1317.e12. Randomized clinical trial assessing the efficacy and safety of benralizumab-mediated eosinophil depletion for treating CRSwNP.

    Article  CAS  PubMed  Google Scholar 

  48. Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51:836–44.

    Article  CAS  PubMed  Google Scholar 

  49. •• Takabayashi T, Asaka D, Okamoto Y, Himi T, Haruna S, Yoshida N, et al. A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis. Am J Rhinol Allergy. 2021;35:861–70. Randomized clinical trial assessing the efficacy and safety of benralizumab

    Article  PubMed  Google Scholar 

  50. Yang SK, Cho S-H, Kim DW. Interpretation of clinical efficacy of biologics in chronic rhinosinusitis with nasal polyps via understanding the local and systemic pathomechanisms. Allergy Asthma Immunol Res. 2022;14:465–78.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Bandi F, Gallo S, Preti A, Mozzanica F, Visca D, Marelli M, et al. Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients. Acta Otorhinolaryngol Ital. 2020;40:435–43.

    Article  PubMed  Google Scholar 

  52. Dennis SK, Lam K, Luong A. A review of classification schemes for chronic rhinosinusitis with nasal polyposis endotypes. Laryngoscope Investig Otolaryngol. 2016;1:130–4.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Seccia V, D’Amato M, Scioscia G, Bagnasco D, Di Marco F, Fadda G, et al. Management of patients with severe asthma and chronic rhinosinusitis with nasal polyps: a multidisciplinary shared approach. J Pers Med. 2022;12:1096.

    Article  PubMed  PubMed Central  Google Scholar 

  54. De Corso E, Bellocchi G, De Benedetto M, Lombardo N, Macchi A, Malvezzi L, et al. Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital. 2022;42:1–16.

  55. D’Amato M, Menzella F, Altieri E, Bargagli E, Bracciale P, Brussino L, et al. Benralizumab in patients with severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: an ANANKE study post-hoc analysis. Front Allergy. 2022;3: 881218.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Briegel I, Felicio-Briegel A, Mertsch P, Kneidinger N, Haubner F, Milger K. Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP. J Allergy Clin Immunol Pract. 2021;9:4477–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Otolaryngology Head and Neck Surgery, Fondazione Policlinico Universitario A. Gemelli IRCSS, Rome, Italy

    Eugenio De Corso

  2. UOSD Malattie Respiratorie “Federico II”, Ospedale Monaldi, AO Dei Colli, Naples, Italy

    Maria D’Amato

  3. Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University “Aldo Moro”, Bari, Italy

    Giovanna Elisiana Carpagnano

  4. Dipartimento Di Scienze Della Salute, Università Magna Graecia, Catanzaro, Italy

    Girolamo Pelaia

  5. Department of Cardiovascular and Thoracic Sciences, Università Cattolica Sacro Cuore, Rome, Italy

    Matteo Bonini

  6. Department of Clinical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy

    Matteo Bonini

Authors
  1. Eugenio De Corso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria D’Amato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanna Elisiana Carpagnano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Girolamo Pelaia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matteo Bonini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eugenio De Corso.

Ethics declarations

Conflict of Interest

EDC: lecture fees and participations in experts’ board meeting of GSK, Novartis, Sanofi, Astrazeneca. MDA: speaker and advisory board fees from AstraZeneca, Glaxo Smith Kline and Sanofi. GEC: lecture fees and participations in experts board meeting of GSK, Chiesi, Grifols, Boehringer Ingelheim Sanofi, Astrazeneca Girolamo Pelaia: lecture fees and participations in expert board meetings of AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Guidotti, Menarini, Novartis, Sanofi. MB: speaker and advisory board fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Glaxo Smith Kline, Menarini and Sanofi.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De Corso, E., D’Amato, M., Carpagnano, G.E. et al. The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma. Curr Allergy Asthma Rep 23, 237–248 (2023). https://doi.org/10.1007/s11882-023-01074-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-023-01074-1

Keywords

Search

Navigation